Espino-Grosso, P., Monsour, C
The following sources are referenced in this article: Brito, Sci Rep 2022 Choi, Ann Dermatol 2016 Eisenberg, Nat Med 2018 Han, Biomed Res Int 2015 Haroon, Biomedicines 2023 Kiechl, Am J Clin Nutr 2018 Ko, CrystEngComm 2013 Lei, Evid Based Complement Alternat Med 2015 Madeo, Autophagy 2018 No authors listed, Nutr Rev 1946 Noppakun, Arch Dermatol 1986 Panhard, Br J Dermatol 2012 Pasricha, Indian J Dermatol Venereol Leprol 1981 Pasricha, Indian J Dermatol Venereol Leprol 1986 Roy, J Sex Med 2008 Sehrawat, Pigment Int 2017 Sieve, Science 1941 Wood, FASEB J 2009 Yale, Skin Appendage Disord 2020 Zarafonetis, J Invest Dermatol 1950 Join over 300,000 people on our weekly email list.
Semax is a synthetic heptapeptide derived from ACTH(4-10) with a stabilizing Pro-Gly-Pro C-terminal sequence
Molecular mechanisms of Nrf2-mediated antioxidant response
A randomized trial of high-dose (HD) imatinib mesylate (IM) with or without Peg-interferon (PEG-IFN) and GM-CSF as frontline therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)